Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Preclinical Testing of Nalfurafine as an Opioid-sparing Adjuvant that Potentiates Analgesia by the Mu Opioid Receptor-targeting Agonist Morphine.

Kaski SW, White AN, Gross JD, Trexler KR, Wix K, Harland AA, Prisinzano TE, Aubé J, Kinsey SG, Kenakin T, Siderovski DP, Setola V.

J Pharmacol Exp Ther. 2019 Nov;371(2):487-499. doi: 10.1124/jpet.118.255661. Epub 2019 Sep 6.

PMID:
31492823
2.

Role of RGS12 in the differential regulation of kappa opioid receptor-dependent signaling and behavior.

Gross JD, Kaski SW, Schmidt KT, Cogan ES, Boyt KM, Wix K, Schroer AB, McElligott ZA, Siderovski DP, Setola V.

Neuropsychopharmacology. 2019 Sep;44(10):1728-1741. doi: 10.1038/s41386-019-0423-7. Epub 2019 May 29.

PMID:
31141817
3.

Four single nucleotide polymorphisms in genes involved in neuronal signaling are associated with Opioid Use Disorder in West Virginia.

Kaski SW, Brooks S, Wen S, Haut MW, Siderovski DP, Berry JH, Lander LR, Setola V.

J Opioid Manag. 2019 Mar-Apr;15(2):103-109. doi: 10.5055/jom.2019.0491.

PMID:
31057342
4.

Development of Full Sweet, Umami, and Bitter Taste Responsiveness Requires Regulator of G protein Signaling-21 (RGS21).

Schroer AB, Gross JD, Kaski SW, Wix K, Siderovski DP, Vandenbeuch A, Setola V.

Chem Senses. 2018 May 23;43(5):367-378. doi: 10.1093/chemse/bjy024.

5.

Regulator of G protein signaling-12 modulates the dopamine transporter in ventral striatum and locomotor responses to psychostimulants.

Gross JD, Kaski SW, Schroer AB, Wix KA, Siderovski DP, Setola V.

J Psychopharmacol. 2018 Feb;32(2):191-203. doi: 10.1177/0269881117742100. Epub 2018 Jan 24.

Supplemental Content

Loading ...
Support Center